- Home
- MFIN vs CADL Comparison
MFIN vs CADL Comparison
Compare MFIN & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- CADL
- Stock Information
- Founded
- MFIN 1995
- CADL 1999
- Country
- MFIN United States
- CADL United States
- Employees
- MFIN N/A
- CADL N/A
- Industry
- MFIN Finance: Consumer Services
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- CADL Health Care
- Exchange
- MFIN Nasdaq
- CADL Nasdaq
- Market Cap
- MFIN 207.3M
- CADL 234.8M
- IPO Year
- MFIN 1996
- CADL 2021
- Fundamental
- Price
- MFIN $9.17
- CADL $5.45
- Analyst Decision
- MFIN
- CADL Strong Buy
- Analyst Count
- MFIN 0
- CADL 4
- Target Price
- MFIN N/A
- CADL $21.00
- AVG Volume (30 Days)
- MFIN 41.3K
- CADL 991.5K
- Earning Date
- MFIN 07-29-2025
- CADL 05-13-2025
- Dividend Yield
- MFIN 3.60%
- CADL N/A
- EPS Growth
- MFIN N/A
- CADL N/A
- EPS
- MFIN 1.60
- CADL N/A
- Revenue
- MFIN $316,751,000.00
- CADL N/A
- Revenue This Year
- MFIN N/A
- CADL N/A
- Revenue Next Year
- MFIN $5.24
- CADL N/A
- P/E Ratio
- MFIN $5.73
- CADL N/A
- Revenue Growth
- MFIN 13.91
- CADL N/A
- 52 Week Low
- MFIN $6.48
- CADL $3.79
- 52 Week High
- MFIN $10.50
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- MFIN 50.42
- CADL 50.27
- Support Level
- MFIN $9.14
- CADL $5.18
- Resistance Level
- MFIN $9.48
- CADL $6.29
- Average True Range (ATR)
- MFIN 0.31
- CADL 0.41
- MACD
- MFIN -0.02
- CADL 0.08
- Stochastic Oscillator
- MFIN 44.83
- CADL 42.89
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.